CRMD Stock Summary and Trading Ideas (Cormedix | NASDAQ:CRMD)

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.

Cormedix trades on the NASDAQ stock market under the symbol CRMD.

As of April 24, 2024, CRMD stock price declined to $5.33 with 406,653 million shares trading.

CRMD has a beta of 0.97, meaning it tends to be less sensitive to market movements. CRMD has a correlation of 0.03 to the broad based SPY ETF.

CRMD has a market cap of $293.05 million. This is considered a Small Cap stock.

Last quarter Cormedix reported $0 in Revenue and -$.26 earnings per share. This beat revenue expectation by $250,000 and missed earnings estimates by -$.06.

In the last 3 years, CRMD stock traded as high as $8.94 and as low as $2.57.

The top ETF exchange traded funds that CRMD belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

CRMD stock has underperformed the market in the last year with a return of +7.0%, while SPY returned +24.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CRMD shares. However, CRMD has outperformed the market in the last 3 month and 2 week periods, returning +62.5% and +12.2%, while SPY returned +4.6% and -2.7%, respectively. This indicates CRMD has been having a stronger performance recently.

CRMD support price is $5.12 and resistance is $5.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRMD stock will trade within this expected range on the day.